GAM Holding AG Sells 30,371 Shares of Omnicell, Inc. (NASDAQ:OMCL)

GAM Holding AG decreased its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 36.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 51,972 shares of the company's stock after selling 30,371 shares during the quarter. GAM Holding AG owned 0.11% of Omnicell worth $2,266,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in OMCL. Vanguard Group Inc. grew its holdings in shares of Omnicell by 8.5% during the fourth quarter. Vanguard Group Inc. now owns 5,571,420 shares of the company's stock valued at $209,653,000 after buying an additional 434,336 shares during the last quarter. Diversified Trust Co boosted its holdings in Omnicell by 18.5% in the first quarter. Diversified Trust Co now owns 14,870 shares of the company's stock worth $435,000 after purchasing an additional 2,326 shares during the last quarter. Tributary Capital Management LLC boosted its holdings in Omnicell by 4.0% in the first quarter. Tributary Capital Management LLC now owns 315,158 shares of the company's stock worth $9,212,000 after purchasing an additional 12,243 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Omnicell by 3.9% in the first quarter. Principal Financial Group Inc. now owns 264,083 shares of the company's stock worth $7,719,000 after purchasing an additional 9,944 shares during the last quarter. Finally, Arkadios Wealth Advisors boosted its holdings in Omnicell by 30.6% in the first quarter. Arkadios Wealth Advisors now owns 30,010 shares of the company's stock worth $877,000 after purchasing an additional 7,025 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Price Performance

NASDAQ:OMCL traded down $1.17 on Wednesday, reaching $39.93. 362,712 shares of the company's stock traded hands, compared to its average volume of 517,218. The stock has a 50-day simple moving average of $43.21 and a 200-day simple moving average of $34.52. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $45.84. The firm has a market cap of $1.84 billion, a PE ratio of -89.35, a P/E/G ratio of 45.31 and a beta of 0.83. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The company had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. During the same quarter last year, the company earned $0.29 EPS. The firm's quarterly revenue was down 7.4% on a year-over-year basis. Equities research analysts forecast that Omnicell, Inc. will post 0.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on OMCL shares. Bank of America raised their target price on shares of Omnicell from $34.00 to $44.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. JPMorgan Chase & Co. raised their target price on shares of Omnicell from $26.00 to $37.00 and gave the stock a "neutral" rating in a report on Friday, August 23rd. Barclays upgraded shares of Omnicell from an "underweight" rating to an "equal weight" rating and lifted their price target for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. Benchmark restated a "buy" rating and issued a $48.00 price objective on shares of Omnicell in a research note on Wednesday, October 9th. Finally, StockNews.com upgraded Omnicell from a "hold" rating to a "buy" rating in a research report on Saturday. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $41.33.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.